Skip to main content
Top
Published in: Breast Cancer 2/2011

01-04-2011 | Original Article

Sentinel lymph node biopsy using CT lymphography in breast cancer

Authors: Junya Minohata, Shintaro Takao, Kouichi Hirokaga

Published in: Breast Cancer | Issue 2/2011

Login to get access

Abstract

Background

Sentinel lymph node biopsy (SLNB) is a standard surgical procedure for patients with early breast cancer. The combination of radioisotope (RI) and dye staining is the most accurate method for identification of sentinel lymph nodes (SLN). However, institutions without RI centers perform SLNB by blue dye alone. The identification rate with the dye method alone is inferior to the RI combination method. In our institution, the identification rate of SLNBs by the dye method alone was 95%. So we started this study of SLNB using computed tomographic lymphography (CTLG).

Patients and methods

Three hundred twenty-four patients with primary breast cancer and no clinical evidence of lymph node metastasis were studied. Identification of SLN was performed by CTLG and the dye-staining method. The identification rate of SLNs was analyzed for relation with the clinicopathological findings.

Results

The SLN identification rate was 98.5% with CTLG and 98.8% when combined with the dye-staining method. The identification rate with CTLG was significantly lower in the initial cases. CTLG identified the SLNs in all cases 6 months after its induction. Multi-route multi-SLN patterns, in which SLNs were easily missed by the dye method, were detected in 9.6% of the patients. There was a significant difference in the SLN metastasis rates; partial enhancement of the SLN with CTLG had the consequence that the metastasis-positive rate was high.

Conclusion

The SLN identification rate was improved by combining the dye-staining method and CTLG. CTLG has a superior spatial resolution activity for detecting SLNs precisely; making CTLG available for the prediction of metastases has been suggested. It is possible to perform SLNB with high accuracy by using CTLG in the institutions that do not have RI.
Literature
1.
go back to reference Tangoku A, Yamamoto S, Suga K, Ueda K, Nagashima Y, Hida M, et al. Sentinel lymph node biopsy using computed tomography-lymphography in patients with breast cancer. Surgery. 2004;135:258–65.PubMedCrossRef Tangoku A, Yamamoto S, Suga K, Ueda K, Nagashima Y, Hida M, et al. Sentinel lymph node biopsy using computed tomography-lymphography in patients with breast cancer. Surgery. 2004;135:258–65.PubMedCrossRef
2.
go back to reference Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomized controlled study. Lancet Oncol. 2006;7(12):983–90.PubMedCrossRef Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomized controlled study. Lancet Oncol. 2006;7(12):983–90.PubMedCrossRef
3.
go back to reference Motomura K, Inaji H, Komoike Y, Hasegawa Y, Kasugai T, Noguchi S, et al. Combination technique is superior to dye alone in identification of the sentinel node in breast cancer patients. J Surg Oncol. 2001;76:95–9.PubMedCrossRef Motomura K, Inaji H, Komoike Y, Hasegawa Y, Kasugai T, Noguchi S, et al. Combination technique is superior to dye alone in identification of the sentinel node in breast cancer patients. J Surg Oncol. 2001;76:95–9.PubMedCrossRef
4.
go back to reference Radovanovic Z, Golubovic A, Plzak A, Stojiljkovic B, Radovanovic D. Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer. Eur J Surg Oncol. 2004;30(9):913–7.PubMed Radovanovic Z, Golubovic A, Plzak A, Stojiljkovic B, Radovanovic D. Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer. Eur J Surg Oncol. 2004;30(9):913–7.PubMed
5.
go back to reference Takahashi M, Sasa M, Hirose C, Hisaoka S, Taki M, Hirose T, et al. Clinical efficacy and problems with CT lymphography in identifying the sentinel node in breast cancer. World J Surg Oncol. 2008;6:57.PubMedCrossRef Takahashi M, Sasa M, Hirose C, Hisaoka S, Taki M, Hirose T, et al. Clinical efficacy and problems with CT lymphography in identifying the sentinel node in breast cancer. World J Surg Oncol. 2008;6:57.PubMedCrossRef
6.
go back to reference Kitai T, Inomoto T, Miwa M, Shikayama T. Fluorescence navigation with indocyanine green for detection sentinel lymph nodes in breast cancer. Breast Cancer. 2005;12:211–5.PubMedCrossRef Kitai T, Inomoto T, Miwa M, Shikayama T. Fluorescence navigation with indocyanine green for detection sentinel lymph nodes in breast cancer. Breast Cancer. 2005;12:211–5.PubMedCrossRef
7.
go back to reference Minohata J, Tatsumi K, Yoshida A, Ishikawa Y, Wakuya J. Sentinel lymph node biopsy using CT-lymphography with ICG fluorescence navigation in breast cancer. Jpn J Breast Cancer. 2009;24(2):183–8. Minohata J, Tatsumi K, Yoshida A, Ishikawa Y, Wakuya J. Sentinel lymph node biopsy using CT-lymphography with ICG fluorescence navigation in breast cancer. Jpn J Breast Cancer. 2009;24(2):183–8.
8.
go back to reference Suga K, Yuan Y, Okada M, Matsunaga N, Tangoku A, Yamamoto S, et al. Breast sentinel lymph node mapping at CT lymphography with iopamidol: preliminary experience. Radiology. 2004;230:543–52.PubMedCrossRef Suga K, Yuan Y, Okada M, Matsunaga N, Tangoku A, Yamamoto S, et al. Breast sentinel lymph node mapping at CT lymphography with iopamidol: preliminary experience. Radiology. 2004;230:543–52.PubMedCrossRef
Metadata
Title
Sentinel lymph node biopsy using CT lymphography in breast cancer
Authors
Junya Minohata
Shintaro Takao
Kouichi Hirokaga
Publication date
01-04-2011
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2011
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-009-0183-z

Other articles of this Issue 2/2011

Breast Cancer 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine